Older AdultsNCT07799610
Senior Center Medication Safety and Empowerment Curriculum
A study testing Team Alice Medication Safety and Empowerment Curriculum (MedSEC) in people with Older Adults and Medication and Supplement Use, run by State University of New York at Buffalo at 1 site in United States.
Trial summary
Team Alice's Medication Safety and Empowerment Curriculum (MedSEC) helps older adults and caregivers learn how to safely manage medications. Many seniors take multiple medications, which can lead to harmful side effects or unnecessary treatments. Read more about this study
- Who is it for?
- Ages 55 years and older
- Conditions the study is for
- Older Adults, Medication and Supplement Use, Caregiver Awareness
- What is being tested?
- Team Alice Medication Safety and Empowerment Curriculum (MedSEC)
- How many people
- 125 participants
- Where
- 1 siteUnited States
- Study dates
- 1 Feb 2026to 31 Mar 2027
- Phase
- Interventional
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 55 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- 55 years of age and above
- taking prescription medications
- Carepartner Inclusion Criteria:
- currently an informal or formal care partner for an eligible patient (regardless of whether they live with or near the patient)
- aged 18 years of age and above
Who cannot join
- Patients with cognitive impairment that prevents their self-management of medications.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site, 1 recruiting
- Recruiting
University at Buffalo
Buffalo, New York, 142148033
Robert G Wahler, Doctor of Pharmacy, 7166454777, rgwahler@buffalo.edu
Robert G Wahler, Doctor of Pharmacy
About this study
Official title: Team Alice Senior Center Medication Safety and Empowerment Curriculum
Team Alice's Medication Safety and Empowerment Curriculum (MedSEC) helps older adults and caregivers learn how to safely manage medications. Many seniors take multiple medications, which can lead to harmful side effects or unnecessary treatments. This program, developed at the University at Buffalo, will be offered at senior centers in Western New York. It includes two interactive sessions that teach participants how to recognize medication risks and talk with their doctors about safer options. The curriculum uses videos, group discussions, and hands-on tools to build confidence and knowledge. It follows the "4Ms" of Age-Friendly Health Systems: What Matters, Medication, Mentation, and Mobility. A "Train-the-Trainer" model will help senior center staff continue the program long-term. The goal is to reduce medication harm, improve communication with healthcare providers, and support healthy aging in the community.
- Conditions
- Older Adults, Medication and Supplement Use, Caregiver Awareness, Health Literacy, Empowerment, Patient, Knowledge
- Being tested
- Team Alice Medication Safety and Empowerment Curriculum (MedSEC)
- Keywords
- older adult, patient education, caregiver education, medication safety, patient knowledge, patient empowerment
- Medical subject headings
- Patient Participation
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Team Alice Medication Safety and Empowerment Curriculum (MedSEC)Other
A two-part interactive curriculum that will improve medication safety awareness and empower participants to engage in conversations with healthcare providers. The focus of this study will be to evaluate the impact of the MedSEC on patient/care-partner knowledge and medication management patient activation levels. A pre/post study that surveys older adults/caregivers pre-curriculum intervention and post-curriculum intervention, in addition to 6 months after program completion.
What is being measured
The primary outcome is the main question the study is designed to answer.
Evaluate the impact of the MedSEC on patient/care-partner knowledge and activation levels in managing medications through the Patient Activation Measure (PAM)
Study seeks to enhance patient and care-partner activation, reduce polypharmacy and the use of potentially inappropriate medications (PIMs), and improve shared decision-making through the Patient Activation Measure (PAM).
Measured: Change from baseline (Day 1), post-program assessment (immediately after educational session 2, Day 7), and 6 months after program completion.
Evaluate the impact of the MedSEC on patient/care-partner knowledge and activation levels in managing medications through the Revised Patient Attitudes Towards Deprescribing (rPATD) questionnaires.
Study seeks to enhance patient and care-partner activation, reduce polypharmacy and the use of potentially inappropriate medications (PIMs), and improve shared decision-making through the Revised Patient Attitudes Towards Deprescirbing (rPATD) questionnaires.
Measured: Change from baseline (Day 1), post-program assessment (immediately after educational session 2, Day 7), and 6 months after program completion.
Secondary outcomes (4)
Change from Baseline in participant understanding of medication safety risks at 6 Months.
85% of participants will demonstrate an understanding of medication safety risks through pre- and post-program patient/caregiver questionnaires, including the Patient Activation Measure (PAM) and Revised Patient Attitudes to Deprescribing (rPATD). Additional questions pertaining to knowledge retention and actionability will be asked at 6 months.
Measured: Change from baseline (Day 1), post-program assessment (immediately after educational session 2, Day 7), and 6 months after program completion.
Participants will demonstrate knowledge of the 4Ms (Age-Friendly Health System) framework through pre/post/6 month follow up questionnaires.
By the end of the program, 80% of participants will demonstate knowledge of the 4Ms framework, measured by four questions related to the 4Ms and the Age-Friendly Health System taken prior to the program, immediately post-program, and 6 months after program completion.
Measured: Change from baseline, post-program assessment (immediately after program completion), and 6 months after program completion.
Change in patient engagement as measured by the Patient Activation Measure (PAM) from baseline to 6 months post program.
6 months post-program, 65% of participants will show improved patient engagement, as measured by the Patient Activation Measure (PAM) questionnaire.
Measured: Change from baseline (Day 1), post-program assessment (immediately after educational session 2, Day 7), and 6 months after program completion.
Change from baseline in the mean of medications after 6 months follow-up
Within 6 months of completing program, 50% of participants with polypharmacy will have reduced medication usage by 10%. (mean # of medications.)
Measured: Change from baseline and 6 months after program completion.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted2 Sep 2026
- Study start1 Feb 2026
- Primary completion1 Feb 2027 (estimated)
- Study completion31 Mar 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Older AdultsStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 125 participants (estimated)
Sponsor and investigators
- Lead sponsor
- State University of New York at Buffalo
- Sponsor type
- University, hospital or other
- Collaborators
- Health Foundation for Western and Central New York
- Responsible party
- Principal investigator, Robert Wahler, State University of New York at Buffalo
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07799610
- Sponsor's protocol ID
- STUDY00009882
- Other IDs
- G-202509-02155
- Status last verified
- Aug 2026
- First submitted
- 21 Nov 2025
- Last updated
- 2 Sep 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No